Literature DB >> 31673783

Initial pulmonary metastasis after pancreatectomy for pancreatic ductal adenocarcinoma.

Tetsunosuke Shimizu1, Kohei Taniguchi2,3, Mitsuhiro Asakuma2, Koji Komeda2, Yoshihiro Inoue2, Sang-Woong Lee2, Fumitoshi Hirokawa2, Kazuhisa Uchiyama2.   

Abstract

Patients who undergo pancreatectomy for pancreatic ductal adenocarcinoma (PDA) develop relatively early recurrence, but pulmonary metastasis from PDA is rare. Between January 2008 and December 2016, a total of 120 consecutive patients underwent pancreatectomy for primary PDA at Osaka Medical College Hospital. Among these, 13 patients developed pulmonary metastasis and 6 patients underwent pulmonary metastasectomy. Among these patients, the median disease-free survival following initial pancreatic surgery was 26.1 months, and the median overall survival (OS) interval was 39 months. On the other hand, seven patients did not undergo pulmonary resection. The median OS interval of these patients was 33 months. The 1-, 3-, and 5-year OS rates were 100%, 80%, and 60%, respectively, for patients who underwent pulmonary metastasectomy and 100.0%, 42.8%, and 0%, respectively, for those who did not undergo the procedure. Our experience has shown that surgical resection may lengthen the survival time of patients who tolerate surgery.

Entities:  

Keywords:  Metastasectomy; Pancreatic ductal adenocarcinoma; Pulmonary metastasis

Mesh:

Year:  2019        PMID: 31673783     DOI: 10.1007/s00595-019-01902-w

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  1 in total

Review 1.  Locoregional Treatment of Metastatic Pancreatic Cancer Utilizing Resection, Ablation and Embolization: A Systematic Review.

Authors:  Florentine E F Timmer; Bart Geboers; Sanne Nieuwenhuizen; Evelien A C Schouten; Madelon Dijkstra; Jan J J de Vries; M Petrousjka van den Tol; Martijn R Meijerink; Hester J Scheffer
Journal:  Cancers (Basel)       Date:  2021-03-31       Impact factor: 6.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.